GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Angion Biomedica Corp (NAS:ANGN) » Definitions » Shares Outstanding (EOP)

Angion Biomedica (Angion Biomedica) Shares Outstanding (EOP) : 30.11 Mil (As of Mar. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Angion Biomedica Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Angion Biomedica's shares outstanding for the quarter that ended in Mar. 2023 was 30.11 Mil.

Angion Biomedica's quarterly shares outstanding increased from Dec. 2022 (30.11 Mil) to Mar. 2023 (30.11 Mil). It means Angion Biomedica issued new shares from Dec. 2022 to Mar. 2023 .

Angion Biomedica's annual shares outstanding increased from Dec. 2021 (29.96 Mil) to Dec. 2022 (30.11 Mil). It means Angion Biomedica issued new shares from Dec. 2021 to Dec. 2022 .


Angion Biomedica Shares Outstanding (EOP) Historical Data

The historical data trend for Angion Biomedica's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Angion Biomedica Shares Outstanding (EOP) Chart

Angion Biomedica Annual Data
Trend Dec12 Dec13 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial 15.36 16.90 28.78 29.96 30.11

Angion Biomedica Quarterly Data
Jun13 Dec13 Mar14 Jun14 Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.96 30.05 30.11 30.11 30.11

Competitive Comparison of Angion Biomedica's Shares Outstanding (EOP)

For the Biotechnology subindustry, Angion Biomedica's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Angion Biomedica's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Angion Biomedica's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Angion Biomedica's Shares Outstanding (EOP) falls into.



Angion Biomedica Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Angion Biomedica  (NAS:ANGN) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Angion Biomedica Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Angion Biomedica's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Angion Biomedica (Angion Biomedica) Business Description

Traded in Other Exchanges
N/A
Address
7-57 Wells Avenue, Suite 14, Newton, MA, USA, 02459
Angion Biomedica Corp is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Its product candidate, ANG-3777, is a hepatocyte growth factor (HGF) mimetic that is evaluating in multiple acute organ injuries and related indications, including acute kidney injury (AKI) and injuries to other major organs, such as the lungs, central nervous system (CNS) and heart; acute lung injury (ALI), with a primary focus on acute respiratory distress syndrome (ARDS), and acute CNS injuries. It is advancing multiple programs for the treatment of fibrotic diseases, leading to ANG-3070, a tyrosine kinase inhibitor (TKI), and inhibitor of rho kinase 2 (ROCK2).
Executives
Jay Venkatesan director, officer: See Remarks C/O AYER CAPITAL MANAGEMENT, LP, 230 CALIFORNIA ST, SUITE 600, SAN FRANCISCO CA 94111
Allen Nissenson director 601 HAWAII ST., EL SEGUNDO CA 90245
John F. Neylan officer: See Remarks 750 LEXINGTON AVENUE, NEW YORK NY 10022
Gregory S Curhan officer: See Remarks 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Jennifer J Rhodes officer: See Remarks C/O ADAMAS PHARMACEUTICALS INC., 1900 POWELL ST., SUITE 750, EMERYVILLE CA 94608
Itzhak Goldberg officer: See Remarks 51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
Victor F Ganzi director
Gilbert S Omenn director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Karen J Wilson director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Eisa-abc Llc 10 percent owner C/O ANGION BIOMEDICA CORP., 51 CHARLES LINDBERGH BOULEVARD, UNIONDALE NY 11553